SLU-PP-332 Dosage, Reconstitution & Mixing Trends

Explore slu-pp-332 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized slu-pp-332 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What SLU-PP-332 Is

SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ), most often sourced for metabolic and "exercise-mimetic" research after 2023 mouse studies. It is not a peptide and not a SARM. No clinical trial has been run and no human safety data exist; it ships as a research powder, typically dissolved for injection in published animal work.[1][2][3]

The estrogen-related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors — they do not bind estrogen despite the name — that act as master transcriptional regulators of mitochondrial-biogenesis, fatty-acid-oxidation, and oxidative-phosphorylation gene programs.[1] SLU-PP-332 is a pan-ERR agonist that drives transcriptional upregulation of these mitochondrial and energy-metabolism programs across skeletal muscle, brown adipose tissue, and liver, producing the exercise-mimetic metabolic phenotype in mice.[2] The molecule is administered by intraperitoneal injection in published in-vivo work.

Billon et al. (J Med Chem 2023) characterised SLU-PP-332 as a pan-ERR agonist with metabolic and exercise-mimetic effects in mice.[2] Earlier Burris-lab work characterised the SLU-PP series chemistry and ERR pharmacology in detail.[1] Follow-on academic work has explored SLU-PP-332 in models of heart failure, obesity, and skeletal-muscle adaptation, with the molecule continuing to be used primarily as a pharmacological tool rather than as a clinical candidate.[4][5] There is no registered ClinicalTrials.gov trial of SLU-PP-332 in any indication;[3] consumer use sits entirely outside any clinical framework or human-safety evidence base.

Not FDA-approved. No registered clinical trial. Pre-clinical mouse data only, primarily by parenteral administration. WADA Prohibited List includes metabolic modulators under S4.5. Research-grade material only.

SLU-PP-332 Research Sources

SLU-PP-332 Dosing Context

SLU-PP-332 has a reported half-life of ~2 hours (pre-clinical estimate). The pharmacokinetic reference models an interval of once or twice daily; this is not a measured community cadence or a dosing recommendation. This ERR agonist has a short half-life in animal studies and clears quickly between doses. No human pharmacokinetic data exist. Pharmacokinetic source: Pre-clinical (mouse) data only; not characterised in humans. It is catalogued under Weight Loss on WPA.

SLU-PP-332 Community Calculator Data

171 SLU-PP-332 reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

SLU-PP-332 Research Background and Calculator Data

SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptor (ERR) family — ERR-alpha, ERR-beta, and ERR-gamma — developed at Saint Louis University in the laboratory of Thomas Burris as part of a broader nuclear-receptor pharmacology program. The estrogen-related receptors are orphan nuclear receptors structurally related to the classical estrogen receptors but with no known endogenous ligand; they are master regulators of mitochondrial biogenesis, oxidative metabolism, and Type I (slow-twitch oxidative) muscle fiber programming, and ERR signaling is one of the canonical pathways activated by physical exercise. SLU-PP-332 is the most fully characterized synthetic ERR pan-agonist published to date — the molecule is conceptually positioned as an "exercise mimetic" that engages the same downstream transcriptional programs as endurance training without the training itself. The pivotal preclinical paper — Billon et al., Nature Metabolism (2023) — reported that SLU-PP-332 administration in sedentary mice increased running endurance by roughly 50% and reduced fat mass, with corresponding upregulation of mitochondrial biogenesis markers and a shift toward Type I muscle fiber composition in untrained animals. The molecule sits in the same conceptual lineage as the earlier exercise-mimetic candidates AICAR (an AMPK activator) and GW501516 / Cardarine (a PPAR-delta agonist) from the Narkar/Evans Salk Institute work, but with a different receptor target and a substantially newer publication date.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.